newsfilter
← Latest News
GlobeNewswire·

CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

  • CervoMed reported financial results for Q3 2026, showing cash, cash equivalents, & marketable securities of approximately $19.6 million as of September 30, 2026.
  • The company announced the advancement of its neflamapimod program for dementia with Lewy bodies (DLB) following the publication of clinical & biomarker data & the removal of a prior FDA drug exposure limit.
  • Regulatory support includes the UK Innovation Passport designation for DLB & FDA approval to utilize a 100mg BID dosing regimen based on new pharmacokinetic data.
  • Neflamapimod received an Innovation Passport under the UK ILAP in August 2026 to accelerate time to market for DLB treatment.
  • Two peer-reviewed articles published in October 2026 supported neflamapimod as a potential DLB treatment, including placebo-controlled Phase 2b RewinD-LB results & translational biomarker findings.
  • Preliminary 12-week biomarker data from the Phase 2a trial in nonfluent variant primary progressive aphasia (nfvPPA) showed reduced neurofilament light chain levels.
  • 24-week biomarker data from the nfvPPA trial has been selected for presentation at CTAD 2026 in Boston in mid-November 2026.
  • Enrollment was completed for the Phase 2a RESTORE trial evaluating neflamapimod in recovery after stroke, with topline data expected by the end of 2026.
  • The first patient in the EXPERTS-ALS trial is expected to be dosed in the first quarter of 2027.
  • R&D expenses decreased to approximately $3.7 million in Q3 2026 from $6.0 million in the prior year period due to lower costs from the completed RewinD-LB trial.
  • General & administrative expenses increased to approximately $2.4 million in Q3 2026, driven by higher personnel costs, stock-based compensation, & legal fees.
  • Net loss for the three months ended September 30, 2026, was approximately $5.9 million, down from $7.7 million in the same period of 2025.
  • CervoMed aims to establish a strategic partnership to advance neflamapimod into a Phase 3 trial for DLB & plans to continue evaluating financing alternatives.
  • The company expects full topline data from the nfvPPA Phase 2a trial in Q2 2027 & initial 24-week clinical data in March 2027.
Company
Cervomed
Keywords
Nasdaq:CRVO , Cervomed